Special Issue "Photodynamic Therapy in Cancer: Principles, State of the Art, and Future Directions"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 15 October 2023 | Viewed by 121

Special Issue Editors

1. Cell Death Investigation and Therapy Laboratory, Department of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium
2. Cancer Research Institute Ghent, 9000 Ghent, Belgium
Interests: immunogenic cell death; photodynamic therapy; cancer immunotherapy
Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, 23 Gagarin Ave., Nizhny Novgorod 603022, Russia
Interests: cancer cell biology; photodynamic therapy; targeted therapy; nanomedicine
Special Issues, Collections and Topics in MDPI journals
Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, 23 Gagarin Ave., 603022 Nizhny Novgorod, Russia
Interests: brain cancer; photodynamic-driven cancer immunotherapy; immunogenic cell death

Special Issue Information

Dear Colleagues,

Since its discovery more than 100 years ago, photodynamic therapy (PDT) has become a potent strategy for the treatment of many types of cancer. Studies in recent years have allowed the deciphering of many aspects of cell response to PDT and a shift from the view of PDT as the oxidative stress inducer to understanding the complexity of molecular mechanisms controlling cell death and survival under PDT treatment. Moreover, in the past decade, it has become clear that the efficacy of PDT depends largely on the ability to induce immunogenic cell death that enables the activation of the immune system to induce efficient anticancer immunity with long-lasting immunological memory. This Special Issue aims to gather state-of-the-art research articles and comprehensive reviews focusing on the recent progress in discovering the PDT mechanisms and, based on this knowledge, the development of novel PDT agents, protocols, and strategies. Research areas may include, but are not limited to, the following:

  • New PDT agents: on the way to the “ideal” photosensitizer
  • Personalized photodynamic therapy
  • Targeted systems for photodynamic therapy of cancer
  • Nano-based agents and materials for photodynamic therapy of cancer
  • Novel approaches in oxygen-boosted photodynamic therapy of cancer
  • Combination of PDT with other anticancer treatment strategies
  • Photochemistry of PDT-induced damages
  • Molecular mechanisms of cell response to the photodynamic therapy of cancer
  • Cancer cell death modalities induced by photodynamic therapy
  • Immunogenic cell death and photodynamic therapy of cancer
  • PDT-driven cancer immunotherapy
  • Bystander effects in photodynamic therapy of cancer
  • Cancer cells trick to overcome PDT efficiency and how to fight cancer resistance
  • Current clinical trials in PDT of cancer

Dr. Dmitri V. Krysko
Dr. Irina V. Balalaeva
Dr. Tatiana A. Mishchenko
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • anticancer photodynamic therapy
  • photosensitizers
  • photochemical damage
  • nano-drugs
  • drug delivery
  • PDT-induced cell death modalities
  • immunogenic cell death
  • tumor hypoxia
  • bystander effect
  • tumor resistance
  • clinical trials in PDT

Published Papers

This special issue is now open for submission.
Back to TopTop